An increased EHMT2 expression is also found in the late stages of oligodendrocyte differentiation, and shown to contribute to H3K9 methylation and chromatin compaction necessary for differentiation of oligodendrocyte progenitor cells (OPCs) [86], which is impaired in patients with MS [87]. Here, EHMT2 is linked to myeloid sarcoma.